Comparative Antitumor Activity and Intestinal Toxicity of 5′‐Deoxy‐5‐fluorouridine and Its Prodrug Trimethoxybenzoyl‐5′‐deoxy‐5‐fluorocytidine
Authors:
- 1 February 1990
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 81 (2) , 188-195
Abstract
N4‐Trimethoxybenzoyl‐5′‐deoxy‐5‐fluorocytidine (Ro 09–1390), a prodrug of the cytostatic 5′‐deoxy‐5‐fluorouridine (5′‐DFUR), was synthesized with the aim of reducing of the dose‐limiting toxicity of 5′‐DFUR, which is diarrhea. In mice bearing Lewis lung carcinoma, 5′‐DFUR given po produced a substantial amount of 5‐fluorouracil (5‐FU) in the intestinal tract as well as in tumors, where the enzyme pyrimidine nucleoside phosphorylase, essential for conversion of 5′‐DFUR to 5‐FU, is predominantly located. With the oral administration of Ro 09–1390 only a small amount of 5‐FU was formed in the intestine; however, the administration of Ro 09–1390 and 5′‐DFUR at the same dose produced similar amounts of 5‐FU in tumor tissues. These differences in metabolism were reflected in their toxicity and antitumor efficacy. The administration of 5′‐DFUR resulted in damage to the intestinal mucosal membrane and diarrhea in normal mice, whereas Ro 09–1390 was much less toxic to the intestinal tract. As regards antitumor activity, Ro 09–1390 and 5′‐DFUR at equivalent doses inhibited the growth of Lewis lung carcinoma to similar extents. Since Ro 09–1390 was much less toxic to the intestinal tract than 5′‐DFUR, mice bearing Lewis lung carcinoma could be given Ro 09–1390 daily over a longer period and at a higher dose, resulting in a longer survival time.Keywords
This publication has 18 references indexed in Scilit:
- [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].1988
- A randomized comparison of doxifluridine and fluorouracil in colorectal carcinomaEuropean Journal of Cancer and Clinical Oncology, 1988
- Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells.Chemical and Pharmaceutical Bulletin, 1986
- Phase II study of 5?-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanomaCancer Chemotherapy and Pharmacology, 1986
- [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].1985
- THE THERAPEUTIC EFFECTS OF ORALLY-ADMINISTERED 5'-DEOXY-5-FLUOROURIDINE, 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL AND 5-FLUOROURACIL ON EXPERIMENTAL MURINE TUMORS1985
- Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.Chemical and Pharmaceutical Bulletin, 1983
- Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine1980
- Structural Requirements for the Enzymatic Deamination of Cytosine NucleosidesHelvetica Chimica Acta, 1978
- Studies of the enzymatic deamination of cytosine arabinoside—IBiochemical Pharmacology, 1965